EMEA (Europe, Middle East and Africa) Male Hypogonadism Market Report 2017

  • EMEA (Europe, Middle East and Africa) Male Hypogonadism Market Report 2017
  • Pages: 116
  • Shop Price: 4000 USD
  • Published Date: 22-Aug-17
  • Hard Copy: 4000 USD
  • Enterprice Wide License: 8000 USD

In this report, the EMEA Male Hypogonadism market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Male Hypogonadism for these regions, from 2012 to 2022 (forecast)
Europe: Germany, France, UK, Russia, Italy and Benelux;
Middle East: Saudi Arabia, Israel, UAE and Iran;
Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Male Hypogonadism market competition by top manufacturers/players, with Male Hypogonadism sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
Astrazeneca Plc.
Merck & Co. Inc.
Laboratories Genevrier
Allergan Plc.
Endo International Plc.
Ferring
AbbVie Inc.
Eli Lilly and Company Ltd.
Finox Biotech
Teva Pharmaceutical Industries Ltd.
Bayer AG
IBSA Institut Biochimque

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
Testosterone Replacement Therapy
Gonadotropin-Releasing Hormones Therapy

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Male Hypogonadism for each application, including
Kallmann Syndrome
Klinefelters Syndrome
Pituitary Disorders
Others